IRADIMED Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de IRADIMED de 9.8% y 10.7% respectivamente, mientras que el BPA crecerá en un 8.8% al año.

Información clave

9.8%

Tasa de crecimiento de los beneficios

8.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.1%
Tasa de crecimiento de los ingresos	10.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	22 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

IRadimed: Reduce Equity Beta With Upside Capture

Jul 18

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Jul 13

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Feb 05

Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Jan 12

Returns On Capital At IRadimed (NASDAQ:IRMD) Paint A Concerning Picture

Jul 13

iRadimed EPS beats by $0.04, beats on revenue

Apr 30

iRadimed EPS misses by $0.02, beats on revenue

Feb 04

If You Had Bought IRadimed (NASDAQ:IRMD) Stock Five Years Ago, You Could Pocket A 70% Gain Today

Jan 31

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:IRMD - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	81	21	N/A	N/A	2
12/31/2024	73	18	N/A	N/A	2
12/31/2023	66	17	5	13	N/A
9/30/2023	63	16	5	13	N/A
6/30/2023	60	15	7	15	N/A
3/31/2023	56	14	5	13	N/A
12/31/2022	53	13	8	10	N/A
9/30/2022	50	13	9	10	N/A
6/30/2022	48	12	9	10	N/A
3/31/2022	45	10	11	12	N/A
12/31/2021	42	9	11	11	N/A
9/30/2021	38	6	10	10	N/A
6/30/2021	35	5	8	8	N/A
3/31/2021	32	1	5	6	N/A
12/31/2020	32	1	5	6	N/A
9/30/2020	34	4	7	7	N/A
6/30/2020	36	5	8	9	N/A
3/31/2020	39	10	10	11	N/A
12/31/2019	39	10	10	10	N/A
9/30/2019	36	8	9	10	N/A
6/30/2019	34	8	7	7	N/A
3/31/2019	32	7	6	6	N/A
12/31/2018	30	6	7	7	N/A
9/30/2018	29	5	5	5	N/A
6/30/2018	27	3	6	6	N/A
3/31/2018	25	2	5	5	N/A
12/31/2017	23	0	3	3	N/A
9/30/2017	22	1	N/A	4	N/A
6/30/2017	24	3	N/A	6	N/A
3/31/2017	29	5	N/A	7	N/A
12/31/2016	32	7	N/A	9	N/A
9/30/2016	35	8	N/A	10	N/A
6/30/2016	35	9	N/A	9	N/A
3/31/2016	33	8	N/A	9	N/A
12/31/2015	31	8	N/A	8	N/A
9/30/2015	26	5	N/A	4	N/A
6/30/2015	22	4	N/A	3	N/A
3/31/2015	19	3	N/A	3	N/A
12/31/2014	15	2	N/A	3	N/A
9/30/2014	15	2	N/A	4	N/A
6/30/2014	14	2	N/A	3	N/A
3/31/2014	12	2	N/A	2	N/A
12/31/2013	11	2	N/A	1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (9.8% al año) de IRMD es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (9.8% al año) de IRMD crezcan menos que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de IRMD crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (10.7% al año) de IRMD crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 10.7% al año) de IRMD crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de IRMD se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

IRADIMED Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Price target increased by 9.5% to US$57.50

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Price target increased by 14% to US$52.50

IRadimed Corporation Revises Earnings Guidance for the Year 2023

Recent updates

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Now 21% overvalued

Now 21% overvalued after recent price rise

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

Director notifies of intention to sell stock

IRadimed Corporation Approves Initiation of Regular Quarterly Dividend, Payable on January 12, 2024

Director notifies of intention to sell stock

Independent Director recently sold US$122k worth of stock

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

Founder notifies of intention to sell stock

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Price target increased by 9.5% to US$57.50

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Independent Director recently sold US$128k worth of stock

Price target increased by 14% to US$52.50

IRadimed Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023

IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023

Investor sentiment improves as stock rises 16%

Price target increased to US$46.00

IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023

Independent Director exercised options to buy US$87k worth of stock.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022

IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

IRadimed Corporation Announces Board Changes

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Investor sentiment deteriorated over the past week

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Independent Director recently sold US$116k worth of stock

Insufficient new directors

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022

IRadimed: Reduce Equity Beta With Upside Capture

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Insufficient new directors

IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022

Price target decreased to US$40.00

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$53.00

IRadimed Corporation to Report Q1, 2022 Results on Apr 29, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS exceeds analyst expectations

Independent Director notifies of intention to sell stock

COO, CFO & Secretary recently sold US$965k worth of stock

Investor sentiment improved over the past week

IRadimed Corporation Announces Special Share Cash Dividend, Payable on February 24, 2022

iRadimed Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2022

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Full year 2021 earnings: EPS exceeds analyst expectations